Two years ago, Jonathan Friedlaender, Ph.D. was about to enter hospice care because of his advancing melanoma. Today he is almost entirely clear of the disease. As a patient of Dr. Mario Sznol, professor of medicine (medical oncology) in the Melanoma Program at Yale Cancer Center, he had access to clinical trials where he received leading-edge care that worked in the face of his grim prognosis. A remarkable response to a new immunotherapy treatment has Professor Friedlaender making long-term plans again.
Together with his wife, Françoise, he made annual gifts to the Yale Cancer Center and planned on arranging a larger donation through his will. When they learned about the tax and income benefits of the charitable gift annuity, however, they realized that giving sooner presented advantages. They made a significant gift to the melanoma research effort and receive fixed payments from Yale. Funding the annuity with highly appreciated stocks allowed them to avoid much of the capital gains tax they would have paid if the stocks were sold.
Professor Friedlaender is a volunteer caregiver who counsels newly diagnosed cancer patients. Funding research in his lifetime makes him a “hope-giver” as well, he said.